ARS Pharmaceuticals, Inc. has 12 Schedule 13D or 13G filings on record since 2025-07-02. 4 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| RA Capital Management, L.P. | 11.1% | 10,940,977 | SCHEDULE 13D/A, 2025-10-01 | 2025-09-29 |
| Rubric Capital Management LP | 8.06% | 8,000,000 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| James E. Flynn | 7.75% | 7,610,217 | SCHEDULE 13D/A, 2025-08-01 | 2025-07-30 |
| BlackRock, Inc. | 5.3% | 5,218,264 | SCHEDULE 13G, 2026-07-27 | 2026-06-30 |
| Millennium Management LLC | 2.5% | 2,520,937 | SCHEDULE 13G/A, 2026-07-14 | 2026-06-30 |
Purpose of Transaction (Item 4)
RA Capital Management, L.P.
Item 4 is hereby amended and supplemented as follows: On September 29, 2025, the Issuer and certain direct and indirect subsidiaries of the Issuer who may become a party thereto from time to time, as guarantors (the "Guarantors"), and ARS Pharmaceuticals Operations, Inc., a wholly owned subsidiary of the Issuer, as the borrower (the "Borrower" and, collectively with the Guarantors, the "Credit Parties"), entered into a credit agreement (the "Credit Agreement") with RA Capital Agency Services, LLC (as the "Administrative Agent" and as the "Collateral Agent"), and affiliates of OMERS Administration Corporation and RA Capital, as lenders, and such other lenders from time to time party thereto (the "Lenders"), providing for up to $250.0 million of term loans from the Lenders to the Borrower (the "Term Loans"). The proceeds of the Term Loans will be used to (i) fund research, development and other product development and commercialization activities of the Company's products and (ii) for other general corporate purposes.Item 4 of the SCHEDULE 13D/A filed 2025-10-01
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-02 | James E. Flynn | 9.9% | SCHEDULE 13D/A |
| 2025-07-22 | James E. Flynn | 8.79% | SCHEDULE 13D/A |
| 2025-08-01 | James E. Flynn | 7.75% | SCHEDULE 13D/A |
| 2025-10-01 | RA Capital Management, L.P. | 11.1% | SCHEDULE 13D/A |
| 2026-01-21 | BlackRock, Inc. | 5.1% | SCHEDULE 13G |
| 2026-02-13 | Rubric Capital Management LP | 6.27% | SCHEDULE 13G |
| 2026-03-24 | Millennium Management LLC | 5.4% | SCHEDULE 13G |
| 2026-03-31 | Millennium Management LLC | 6% | SCHEDULE 13G/A |
| 2026-04-27 | BlackRock, Inc. | 4.98% | SCHEDULE 13G/A |
| 2026-05-15 | Rubric Capital Management LP | 8.06% | SCHEDULE 13G/A |
| 2026-07-14 | Millennium Management LLC | 2.5% | SCHEDULE 13G/A |
| 2026-07-27 | BlackRock, Inc. | 5.3% | SCHEDULE 13G |
Tools for this story
Each opens in a new tab, filled in for ARS Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.